Potent neutralization of influenza a virus by a single-domain antibody blocking M2 ion channel protein

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Wei, Guowei ^a   Meng, Weixu ^a,b   Guo, Haijiang ^a   Pan, Weiqi ^a,b   Liu, Jinsong ^a   Peng, Tao ^a   Chen, Ling ^a,b   Chen, Chang You ^a  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ION CHANNEL; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY M2 7A; PROTEIN M2; UNCLASSIFIED DRUG; ANTIBODY; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; OLIGONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY ISOLATION; ANTIBODY LIBRARY; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; FEMALE; IN VITRO STUDY; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTON TRANSPORT; PROVOCATION TEST; VIRION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; CAMEL; CELL LINE; CELL STRAIN HEK293; CHEMISTRY; CHROMATOGRAPHY; DOG; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE LIBRARY; HUMAN; IMMUNOLOGY; KINETICS; METHODOLOGY; POLYMERASE CHAIN REACTION; PROTEIN TERTIARY STRUCTURE; SERODIAGNOSIS; SURFACE PLASMON RESONANCE;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; CAMELS; CELL LINE; CHROMATOGRAPHY; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE LIBRARY; HEK293 CELLS; HUMANS; INFLUENZA A VIRUS; ION CHANNELS; KINETICS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; OLIGONUCLEOTIDES; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SURFACE PLASMON RESONANCE; VIRAL MATRIX PROTEINS;

EID: 82555187501     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028309     Document Type: Article

References (51)

1. Poland GA, Jacobson RM, Targonski PV, (2007) Avian and pandemic influenza: an overview. Vaccine 25: 3057-3061.
2. Reid AH, Taubenberger JK, (2003) The origin of the 1918 pandemic influenza virus: a continuing enigma. J Gen Virol 84: 2285-2292.
3. Cohen J, Enserink M, (2009) Swine flu. After delays, WHO agrees: the 2009 pandemic has begun. Science 324: 1496-1497.
4. Kaiser J, (2006) A one-size-fits-all flu vaccine? Science 312: 380-382.
5. Couzin-Frankel J, (2009) Swine flu outbreak. What role for antiviral drugs? Science 324: 705.
6. Schmidtke M, Zell R, Bauer K, Krumbholz A, Schrader C, et al. (2006) Amantadine resistance among porcine H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany between 1981 and 2001. Intervirology 49: 286-293.
7. Richman DD, (1996) The implications of drug resistance for strategies of combination antiviral chemotherapy. Antiviral Res 29: 31-33.
8. Hayden FG, Hay AJ, (1992) Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 176: 119-130.
9. Sugrue RJ, Hay AJ, (1991) Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology 180: 617-624.
10. Pinto LH, Holsinger LJ, Lamb RA, (1992) Influenza virus M2 protein has ion channel activity. Cell 69: 517-528.
11. Holsinger LJ, Lamb RA, (1991) Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology 183: 32-43.
12. Helenius A, (1992) Unpacking the incoming influenza virus. Cell 69: 577-578.
13. Lamb RA, Choppin PW, (1981) Identification of a second protein (M2) encoded by RNA segment 7 of influenza virus. Virology 112: 729-737.
14. Fu TM, Grimm KM, Citron MP, Freed DC, Fan J, et al. (2009) Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 27: 1440-1447.
15. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, et al. (2003) Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21: 2616-2626.
16. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, et al. (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5: 1157-1163.
17. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, et al. (1995) Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13: 1399-1402.
18. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, et al. (2007) Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13: 426-435.
19. Feng J, Zhang M, Mozdzanowska K, Zharikova D, Hoff H, et al. (2006) Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 3: 102.
20. Wang R, Song A, Levin J, Dennis D, Zhang NJ, et al. (2008) Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 80: 168-177.
21. Keller MA, Stiehm ER, (2000) Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 13: 602-614.
22. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR, (1990) Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 64: 1375-1377.
23. Zebedee SL, Lamb RA, (1988) Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 62: 2762-2772.
24. Liu W, Zou P, Chen YH, (2004) Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett 93: 131-136.
25. Grandea AG 3rd, Olsen OA, Cox TC, Renshaw M, Hammond PW, et al. (2010) Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A 107: 12658-12663.
26. Fu TM, Freed DC, Horton MS, Fan J, Citron MP, et al. (2009) Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology 385: 218-226.
27. Jegerlehner A, Schmitz N, Storni T, Bachmann MF, (2004) Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172: 5598-5605.
28. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, et al. (1993) Naturally occurring antibodies devoid of light chains. Nature 363: 446-448.
29. De Genst E, Silence K, Decanniere K, Conrath K, Loris R, et al. (2006) Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A 103: 4586-4591.
30. van der Linden RH, de Geus B, Frenken GJ, Peters H, Verrips CT, (2000) Improved production and function of llama heavy chain antibody fragments by molecular evolution. J Biotechnol 80: 261-270.
31. Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, et al. (2009) General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem 284: 3273-3284.
32. van der Linden RH, Frenken LG, de Geus B, Harmsen MM, Ruuls RC, et al. (1999) Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta 1431: 37-46.
33. Ewert S, Cambillau C, Conrath K, Pluckthun A, (2002) Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains. Biochemistry 41: 3628-3636.
34. Saerens D, Pellis M, Loris R, Pardon E, Dumoulin M, et al. (2005) Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J Mol Biol 352: 597-607.
35. Sambrook J, Russell DW, (2001) Molecular cloning: a laboratory manual. 3rd ed Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
36. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S, (1997) Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 414: 521-526.
37. Kurtz S, Luo G, Hahnenberger KM, Brooks C, Gecha O, et al. (1995) Growth impairment resulting from expression of influenza virus M2 protein in Saccharomyces cerevisiae: identification of a novel inhibitor of influenza virus. Antimicrob Agents Chemother 39: 2204-2209.
38. Ilyinskii PO, Gabai VL, Sunyaev SR, Thoidis G, Shneider AM, (2007) Toxicity of influenza A virus matrix protein 2 for mammalian cells is associated with its intrinsic proton-channeling activity. Cell Cycle 6: 2043-2047.
39. Hu W, Zeng S, Li C, Jie Y, Li Z, et al. (2010) Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library. J Med Chem 53: 3831-3834.
40. Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W, (2004) A "universal" human influenza A vaccine. Virus Res 103: 173-176.
41. Black RA, Rota PA, Gorodkova N, Klenk HD, Kendal AP, (1993) Antibody response to the M2 protein of influenza A virus expressed in insect cells. J Gen Virol 74 (Pt 1): 143-146.
42. Liu W, Li H, Chen YH, (2003) N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol Med Microbiol 35: 141-146.
43. Fan J, Liang X, Horton MS, Perry HC, Citron MP, et al. (2004) Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22: 2993-3003.
44. Forsman A, Beirnaert E, Aasa-Chapman MM, Hoorelbeke B, Hijazi K, et al. (2008) Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol 82: 12069-12081.
45. Harmsen MM, van Solt CB, Fijten HP, van Keulen L, Rosalia RA, et al. (2007) Passive immunization of guinea pigs with llama single-domain antibody fragments against foot-and-mouth disease. Vet Microbiol 120: 193-206.
46. van der Vaart JM, Pant N, Wolvers D, Bezemer S, Hermans PW, et al. (2006) Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. Vaccine 24: 4130-4137.
47. Beerli RR, Bauer M, Schmitz N, Buser RB, Gwerder M, et al. (2009) Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virol J 6: 224.
48. Song JM, Wang BZ, Park KM, Van Rooijen N, Quan FS, et al. (2011) Influenza Virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 6: 14538-14548.
49. Yau KY, Dubuc G, Li S, Hirama T, Mackenzie CR, et al. (2005) Affinity maturation of a V(H)H by mutational hotspot randomization. J Immunol Methods 297: 213-224.
50. Schnell JR, Chou JJ, (2008) Structure and mechanism of the M2 proton channel of influenza A virus. Nature 451: 591-595.
51. Stouffer AL, Acharya R, Salom D, Levine AS, Di Costanzo L, et al. (2008) Structural basis for the function and inhibition of an influenza virus proton channel. Nature 451: 596-599.